tetano
Editor, Senior Moderator
Cardiol Res
. 2024 Jun;15(3):179-188.
doi: 10.14740/cr1645. Epub 2024 Jun 25. Effect of Aspirin Use on the Adverse Outcomes in Patients Hospitalized for COVID-19
Poornima Vinod[SUP] 1 2 [/SUP], Vinod Krishnappa[SUP] 1 [/SUP], William Rathell Jr[SUP] 1 [/SUP], Saira Amir[SUP] 3 [/SUP], Subrina Sundil[SUP] 4 [/SUP], Godwin Dogbey[SUP] 5 [/SUP], Hiten Patel[SUP] 6 [/SUP], William Herzog[SUP] 6 7 [/SUP]
Affiliations
Background: Coronavirus disease 2019 (COVID-19) triggers multiple components of the immune system and causes inflammation of endothelial walls across vascular beds, resulting in respiratory failure, arterial and venous thrombosis, myocardial injury, and multi-organ failure leading to death. Early in the COVID-19 pandemic, aspirin was suggested for the treatment of symptomatic individuals, given its analgesic, antipyretic, anti-inflammatory, anti-thrombotic, and antiviral effects. This study aimed to evaluate the association of aspirin use with various clinical outcomes in patients hospitalized for COVID-19.
Methods: This was a retrospective study involving patients aged ≥ 18 years and hospitalized for COVID-19 from March 2020 to October 2020. Primary outcomes were acute cardiovascular events (ST elevation myocardial infarction (STEMI), type 1 non-ST elevation myocardial infarction (NSTEMI), acute congestive heart failure (CHF), and acute stroke) and death. Secondary outcomes were respiratory failure, need for mechanical ventilation, and acute deep vein thrombosis (DVT)/pulmonary embolism (PE).
Results: Of 376 patients hospitalized for COVID-19, 128 were taking aspirin. Significant proportions of native Americans were hospitalized for COVID-19 in both aspirin (22.7%) and non-aspirin (24.6%) groups. Between aspirin and non-aspirin groups, no significant differences were found with regard to mechanical ventilator support (21.1% vs. 15.3%, P = 0.16), acute cardiovascular events (7.8% vs. 5.2%, P = 0.32), acute DVT/PE (3.9% vs. 5.2%, P = 0.9), readmission rate (13.3% vs. 12.9%, P = 0.91) and mortality (23.4% vs. 20.2%, P = 0.5); however, the median duration of mechanical ventilation was significantly shorter (7 vs. 9 days, P = 0.04) and median length of hospitalization was significantly longer (5.5 vs. 4 days, P = 0.01) in aspirin group compared to non-aspirin group.
Conclusion: No significant differences were found in acute cardiovascular events, acute DVT/PE, mechanical ventilator support, and mortality rate between hospitalized COVID-19 patients who were taking aspirin compared to those not taking aspirin. However, larger studies are required to confirm our findings.
Keywords: Acute cerebrovascular accidents; Aspirin; Coronavirus disease 2019; Hypoxia; Mechanical ventilation; Mortality; Non-ST elevation myocardial infarction; ST-elevation myocardial infarction.
. 2024 Jun;15(3):179-188.
doi: 10.14740/cr1645. Epub 2024 Jun 25. Effect of Aspirin Use on the Adverse Outcomes in Patients Hospitalized for COVID-19
Poornima Vinod[SUP] 1 2 [/SUP], Vinod Krishnappa[SUP] 1 [/SUP], William Rathell Jr[SUP] 1 [/SUP], Saira Amir[SUP] 3 [/SUP], Subrina Sundil[SUP] 4 [/SUP], Godwin Dogbey[SUP] 5 [/SUP], Hiten Patel[SUP] 6 [/SUP], William Herzog[SUP] 6 7 [/SUP]
Affiliations
- PMID: 38994222
- PMCID: PMC11236346
- DOI: 10.14740/cr1645
Background: Coronavirus disease 2019 (COVID-19) triggers multiple components of the immune system and causes inflammation of endothelial walls across vascular beds, resulting in respiratory failure, arterial and venous thrombosis, myocardial injury, and multi-organ failure leading to death. Early in the COVID-19 pandemic, aspirin was suggested for the treatment of symptomatic individuals, given its analgesic, antipyretic, anti-inflammatory, anti-thrombotic, and antiviral effects. This study aimed to evaluate the association of aspirin use with various clinical outcomes in patients hospitalized for COVID-19.
Methods: This was a retrospective study involving patients aged ≥ 18 years and hospitalized for COVID-19 from March 2020 to October 2020. Primary outcomes were acute cardiovascular events (ST elevation myocardial infarction (STEMI), type 1 non-ST elevation myocardial infarction (NSTEMI), acute congestive heart failure (CHF), and acute stroke) and death. Secondary outcomes were respiratory failure, need for mechanical ventilation, and acute deep vein thrombosis (DVT)/pulmonary embolism (PE).
Results: Of 376 patients hospitalized for COVID-19, 128 were taking aspirin. Significant proportions of native Americans were hospitalized for COVID-19 in both aspirin (22.7%) and non-aspirin (24.6%) groups. Between aspirin and non-aspirin groups, no significant differences were found with regard to mechanical ventilator support (21.1% vs. 15.3%, P = 0.16), acute cardiovascular events (7.8% vs. 5.2%, P = 0.32), acute DVT/PE (3.9% vs. 5.2%, P = 0.9), readmission rate (13.3% vs. 12.9%, P = 0.91) and mortality (23.4% vs. 20.2%, P = 0.5); however, the median duration of mechanical ventilation was significantly shorter (7 vs. 9 days, P = 0.04) and median length of hospitalization was significantly longer (5.5 vs. 4 days, P = 0.01) in aspirin group compared to non-aspirin group.
Conclusion: No significant differences were found in acute cardiovascular events, acute DVT/PE, mechanical ventilator support, and mortality rate between hospitalized COVID-19 patients who were taking aspirin compared to those not taking aspirin. However, larger studies are required to confirm our findings.
Keywords: Acute cerebrovascular accidents; Aspirin; Coronavirus disease 2019; Hypoxia; Mechanical ventilation; Mortality; Non-ST elevation myocardial infarction; ST-elevation myocardial infarction.